2023 | 2020 | 2016 | 2015 | 2012 | 2011 | 2010 | 2009

2023

Kartha N, Gianopulos JE, Schrank Z, Cavender SM, Dobersch S, Kynnap BD, Wallace-Povirk A, Wladyka CL, Santana JF, Kim JC, Yu A, Bridgwater CM, Fuchs K, Dysinger S, Lampano AE, Notta F, Price DH, Hsieh AC, Hingorani SR, Kugel S. Sirtuin 6 is required for the integrated stress response and resistance to inhibition of transcriptional cyclin-dependent kinases. Sci Transl Med. 2023 May 3;15(694):eabn9674.

2020

Kugel S, Hingorani SR. Cholesterol Biosynthesis Influences Subtype Specificity and Plasticity in Pancreas Cancer. Cancer Cell. 2020 Oct 12;38(4):443-445. doi: 10.1016/j.ccell.2020.09.010. 

2016

Kugel S, Sebastián C, Fitamant J, Ross KN, Saha SK, Jain E, Gladden A, Arora KS, Kato Y, Rivera MN, Ramaswamy S, Sadreyev RI, Goren A, Deshpande V, Bardeesy N & Mostoslavsky R. SIRT6 suppresses pancreatic cancer through control of Lin28b. Cell. 2016. 165(6):1401-15.

2015

*Wilson MR, *Kugel S, Huang J, Wilson LJ, Wloszczynski PA, Ye J, Matherly LH & Hou Z. Structural determinants of human proton-coupled folate transporter oligomerization: role of GXXXG motifs and identification of oligomeric interfaces at transmembrane domains 3 and 6. Biochemical Journal. 2015. 469(1):33-44. *These authors contributed equally to this work.

*Kugel S, *Feldman JL, Klein AM, Silberman DM, Sebastián C, Dobersch S, Clark AR, Getz G, Denu JM & Mostoslavsky R. Identification and molecular basis for SIRT6 loss-of-function point mutations in cancer. Cell Reports. 2015. 13(3):479-88. *These authors contributed equally to this work.

Etchegaray JP, Chavez L, Huang Y, Ross KN, Choi J, Martinez-Pastor B, Walsh RM, Sommer CA, Lienhard M, Gladden A, Kugel S, Silberman DM, Ramaswamy S, Mostoslavsky G, Hochedlinger K, Goren A, Rao A & Mostoslavsky R. The histone deacetylase SIRT6 controls embryonic stem cell fate via Tet-mediated production of 5-hydroxymethylcytosine. Nat. Cell Biol. 2015. 17, 545-557.

2012

Hou Z, Kugel S, Etnyre E, Olive M, Hsiung, B, Cherian C, Wloszczynski PA, Moin K, & Matherly LH. Identification and functional impact of homo-oligomers of the human proton-coupled folate transporter. J Biol Chem. 2012. 287(7): 4982-95.

Wang L, Cherian C, Kugel S, Mitchell-Ryan S, Hou Z, Matherly LH & Gangjee A. Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier. J Med Chem. 2012. 55(4): 1758-70.

Kugel S, Wang L, Polin P, White K, Kushner J, Stout M, Hou Z, Cherian C, Gangjee A & Matherly LH. Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter. Mol Pharmacol. 2012. 82(4): 591-600.

Cherian C, Kugel S, Wang L, Polin L, White K, Kushner J, Stout M, Hou Z, Gangjee A & Matherly LH. Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter. Cancer Chemother Pharmacol. 2012. 71(4): 999-1011.

2011

*Wang L, *Kugel S, Cherian C, Polin L, White K, Kushner J, Fulterer A, Chang MH, Mitchell-Ryan S, Stout M, Romero MF, Hou Z, Matherly LH. & Gangjee A. Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase. J Med Chem. 2011. 54(20): 7150-64. *These authors contributed equally to this work.

Kugel S, Wang L, Polin P, White K, Kushner J, Hales E, Stout M, Hou Z, Cherian C, Gangjee A & Matherly LH. Therapeutic targeting of a novel 6-substituted pyrrolo[2,3d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter. Mol Pharmacol. 2011. 80(6): 1096-107.

2010

Wang, L., Cherian, C., Kugel Desmoulin, S., Polin, L., Deng, Y., Wu, J., Hou, Z., White, K., Kushner, J., Matherly, L.H. & Gangjee, A. Synthesis and biological activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry. J Med Chem. 2010. 53(3): 1306-18.

Kugel S, Wang Y, Wu J, Stout M, Hou Z, Fulterer A, Chang MH, Romero MF, Cherian C, Gangjee A. & Matherly LH. Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors. Mol Pharmacol. 2010. 78(4): 577-87.

2009

Larson Gedman A, Chen Q, Kugel S, Ge Y, LaFiura K, Haska CL, Cherian C, Devidas M, Linda SB, Taub J.W. & Matherly, L.H. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Leukemia. 2009. 23(8): 1417-1425.

Deng Y, Zhou X, Kugel S, Wu J, Cherian C, Hou Z, Matherly LH & Ganjee A. Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry. J. Med. Chem. 2009. 52(9): 2940-2951.